Summary & Overview
HCPCS J9023: Avelumab 10 mg Injection
HCPCS Level II code J9023 denotes a 10 mg injection of avelumab, an immunotherapy agent used in oncology. As a drug-specific HCPCS Level II code, J9023 is used on medical claims to identify the administered biologic separately from the infusion or visit. Nationally, accurate use of this code matters for clinical documentation, billing clarity, and payer adjudication for high-cost oncology therapies.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for avelumab injections, billing considerations tied to HCPCS Level II coding, and typical sites of service where the drug is administered. The publication summarizes common modifiers associated with drug administration in general and notes when data elements are not available in the input.
This report provides practical benchmarks and policy-oriented context relevant to health plans and providers: how the code is used on claims, typical service settings, and the national importance of precise coding for oncology biologic therapies. Data not available in the input are called out where applicable.
Billing Code Overview
HCPCS Level II code J9023 represents an injection of avelumab, dosed per the descriptor as 10 mg. This code covers the drug product when administered as an injectable oncology biologic.
Service type: Drug administration (intravenous infusion or injection)
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic urothelial carcinoma or other FDA‑approved indication for avelumab who presents to an outpatient oncology infusion suite for scheduled immunotherapy. The patient has a recent oncology consultation documenting indication, treatment plan, and baseline labs (CBC, CMP) and is assessed by oncology nursing prior to infusion for vitals, performance status, and checklist screening for contraindications such as active infection or uncontrolled autoimmune disease. The clinician orders J9023 to cover avelumab dosed per weight or fixed schedule; pharmacy verifies dose, prepares the vial dose under sterile compounding conditions, and documents lot number and expiration. On the day of service the patient receives intravenous infusion in the oncology chair or ambulatory infusion center, monitored for infusion reactions; premedication (e.g., antihistamine, acetaminophen) may be administered per protocol. Post‑infusion monitoring occurs for the required observation period; nursing documents administration details, any adverse events, and disposition. Billing for the drug uses HCPCS code J9023 per 10 mg increment with appropriate modifier(s) for payer reporting and reimbursement, and relevant diagnosis codes for the oncologic indication are submitted with the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |